Adiponectin regulates albuminuria and podocyte function in mice

Area of Science:

• Nephrology
• Endocrinology
• Metabolic Syndrome

Background:

• Increased albuminuria is a risk factor for cardiovascular and renal disease, often linked to obesity and diabetes.
• The relationship between early albuminuria and adiposity is not fully understood.
• Adiponectin, a hormone secreted by adipocytes, is investigated as a potential mediator between fat tissue and kidney function.

Purpose of the Study:

• To determine if adiponectin acts as a signaling molecule between adipocytes and the kidney.
• To investigate the role of adiponectin in regulating albuminuria and podocyte function.

Main Methods:

• Studies were conducted in a patient cohort at high risk for diabetes and kidney disease.
• Experiments involved adiponectin-knockout (Ad(-/-)) mice and cultured podocytes.
• Assessed albuminuria, podocyte morphology, AMPK activity, oxidative stress markers, and NADPH oxidase (Nox4) levels.

Main Results:

• Obese patients showed a negative correlation between albuminuria and plasma adiponectin.
• Ad(-/-) mice exhibited increased albuminuria and podocyte foot process effacement.
• Adiponectin and AMPK activation in cultured podocytes reduced albumin permeability and dysfunction, linked to decreased Nox4 expression.
• Adiponectin treatment normalized albuminuria and improved podocyte structure in Ad(-/-) mice, reducing oxidative stress.

Conclusions:

• Adiponectin is a key regulator of albuminuria, potentially acting via the AMPK pathway.
• Adiponectin modulates oxidative stress in podocytes, thereby protecting against kidney damage.
• Findings suggest therapeutic potential for adiponectin in managing albuminuria and related kidney diseases.